Literature DB >> 31009559

Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.

Makoto Fushimi1, Ikuo Fujimori1, Takeshi Wakabayashi1, Tomoaki Hasui1, Youichi Kawakita1, Keisuke Imamura1, Tomoko Kato1, Morio Murakami1, Tsuyoshi Ishii1, Yorifumi Kikko1, Maki Kasahara1, Atsushi Nakatani1, Yuto Hiura1, Maki Miyamoto1, Kumar Saikatendu2, Hua Zou2, Scott Weston Lane2, J David Lawson2, Hiroshi Imoto1.   

Abstract

Anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, is predominantly expressed in the brain and implicated in neuronal development and cognition. However, the detailed function of ALK in the central nervous system (CNS) is still unclear. To elucidate the role of ALK in the CNS, it was necessary to discover a potent, selective, and brain-penetrant ALK inhibitor. Scaffold hopping and lead optimization of N-(2,4-difluorobenzyl)-3-(1 H-pyrazol-5-yl)imidazo[1,2- b]pyridazin-6-amine 1 guided by a cocrystal structure of compound 1 bound to ALK resulted in the identification of (6-(1-(5-fluoropyridin-2-yl)ethoxy)-1-(5-methyl-1 H-pyrazol-3-yl)-1 H-pyrrolo[2,3- b]pyridin-3-yl)((2 S)-2-methylmorpholin-4-yl)methanone 13 as a highly potent, selective, and brain-penetrable compound. Intraperitoneal administration of compound 13 significantly decreased the phosphorylated-ALK (p-ALK) levels in the hippocampus and prefrontal cortex in the mouse brain. These results suggest that compound 13 could serve as a useful chemical probe to elucidate the mechanism of ALK-mediated brain functions and the therapeutic potential of ALK inhibition.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31009559     DOI: 10.1021/acs.jmedchem.8b01630

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

Review 1.  Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects.

Authors:  Mohammed I El-Gamal; Seyed-Omar Zaraei; Moustafa M Madkour; Hanan S Anbar
Journal:  Molecules       Date:  2022-01-05       Impact factor: 4.411

2.  Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design.

Authors:  Ikuo Fujimori; Takeshi Wakabayashi; Morio Murakami; Atsutoshi Okabe; Tsuyoshi Ishii; Aaron McGrath; Hua Zou; Kumar Singh Saikatendu; Hiroshi Imoto
Journal:  ACS Omega       Date:  2020-11-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.